Tumour-agnostic drugs in paediatric cancers.
Loading...
Embargo End Date
ICR Authors
Authors
Chisholm, JC
Carceller, F
Marshall, LV
Carceller, F
Marshall, LV
Document Type
Other
Date
Date Accepted
2020-03-01
Abstract
The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
Citation
British journal of cancer, 2020, 122 (10), pp. 1425 - 1427
Source Title
Publisher
ISSN
0007-0920
eISSN
1532-1827
Collections
Research Team
Sarcoma Clinical Trials in children and young people
Sarcoma Clinical Trials in children and young people
Sarcoma Clinical Trials in children and young people